Seeing the Light: CAR T-cell Targeting of Lambda-restricted B-cell Lymphomas

Area of Science:

• Immunology
• Oncology
• Cell Therapy

Background:

• Chimeric antigen receptor (CAR) T cell therapy targeting CD19 effectively treats B cell malignancies.
• However, CD19-targeted CAR T cells also eliminate all normal B cells, leading to B cell aplasia.
• There is a need for alternative targets that spare normal B cells.

Purpose of the Study:

• To evaluate immunoglobulin light chains as an alternative target for CAR T cell therapy.
• To assess the potential of targeting light chains to preserve normal B cells.

Main Methods:

• Development of CAR T cells targeting immunoglobulin light chains.
• In vitro and in vivo studies to assess efficacy against B cell malignancies and impact on normal B cells.

Main Results:

• CAR T cells targeting immunoglobulin light chains demonstrated efficacy against malignant B cells.
• This targeting strategy preserved approximately half of the normal B cell population.

Conclusions:

• Targeting immunoglobulin light chains represents a viable alternative to CD19 for CAR T cell therapy.
• This approach holds promise for reducing the B cell aplasia associated with current CAR T cell therapies.